ANI Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on ANI Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date ANI Pharmaceuticals Inc Strategy Report
- Understand ANI Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
ANI Pharmaceuticals Inc (ANI) is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals. The company offers pharmaceuticals for central nervous system (CNS) disorders, gastrointestinal, cancer, ophthalmic, metabolic and other diseases. ANI also conducts business as a Contract Development and Manufacturing Organization (CDMO) supporting late-stage development to commercial manufacture of pharmaceutical products including coated/non-coated tablets and capsules, ointments, creams, non-sterile liquids, suspensions, and gels. It markets oncology products, complex formulations, hormones and steroids and controlled substances. The company sells products to wholesale distributors, group purchasing organizations, retail pharmacy chains, and other pharmaceutical companies. ANI is headquartered in Baudette, Minnesota, the US.
Headquarters
United States of America
Address
210 Main Street West, Baudette, Minnesota, 56623
Website
www.anipharmaceuticals.com
Telephone
1 218 6343500
No of Employees
642
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ANIP (NASD)
Revenue (2022)
$486.8M
53.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
139.2%
(2022 vs 2021)
Market Cap*
$1.4B
Net Profit Margin (2022)
XYZ
125.5%
(2022 vs 2021)
* As of and is in US$
ANI Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Liquids | Technology Tansfer | Arimidex |
| Capsules | Formulation Development | Cortenema |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In May, the company received U.S. Food and Drug Administration (FDA) approval for the abbreviated new drug applications (ANDAs) for Methsuximide Capsules and Alendronate Sodium Oral Solution. |
| 2023 | Regulatory Approval | In April, the company received U.S. Food and Drug Administration (FDA) approval for the abbreviated new drug application (ANDA) for Nitrofurantoin Oral Suspension USP, 25 mg/5 ml. |
| 2023 | Regulatory Approval | In April, the company received U.S. Food and Drug Administration (FDA) approval for the abbreviated new drug application (ANDA) for Colestipol Hydrochloride Tablets USP, 1 g. |
Competitor Comparison
| Key Parameters | ANI Pharmaceuticals Inc | Teva Pharmaceutical Industries Ltd | Viatris Inc | Sun Pharmaceutical Industries Ltd | Hikma Pharmaceuticals Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Israel | United States of America | India | United Kingdom |
| City | Baudette | Tel Aviv | Canonsburg | Mumbai | London |
| State/Province | Minnesota | Tel Aviv | Pennsylvania | Maharashtra | England |
| No. of Employees | 642 | 35,001 | 38,000 | 41,000 | 8,967 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Patrick D. Walsh | Chairman | Executive Board | 2020 | 62 |
| Nikhil Lalwani | Chief Executive Officer; President; Director | Executive Board | 2020 | 45 |
| Stephen P. Carey | Chief Financial Officer; Treasurer | Senior Management | 2016 | 52 |
| Krista Davis | Chief Human Resources Officer; Senior Vice President | Senior Management | 2022 | 50 |
| Muthusamy Shanmugam | Head- Research & Development; Chief Operating Officer - NJ Operations; Director | Executive Board | 2021 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward